Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown Sells 1,535 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,437,280. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Regeneron Pharmaceuticals Stock Up 0.9 %

Regeneron Pharmaceuticals stock opened at $1,045.37 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The firm has a market cap of $115.19 billion, a PE ratio of 30.88, a P/E/G ratio of 2.14 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $1,049.50. The firm’s 50 day moving average price is $958.43 and its two-hundred day moving average price is $938.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on REGN. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target for the company. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Bank of America increased their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Finally, UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $998.09.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Eudaimonia Advisors LLC grew its position in Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 11 shares in the last quarter. Team Hewins LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 11 shares during the period. Angeles Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares during the period. Drive Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares during the period. Finally, MCF Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.